Further Information
Spike glycoprotein Receptor-binding domain, S glycoprotein, Spike protein, Omicron variant spike, Omicron variant pseudovirus, Omicron, pseudovirus reporter, reporter virus particle
1.0 mL (0.5mL X 2 vials) for two 96-well plates
Protocol:
click here to download 1. Require BSL-2 or higher working environment
2. 5 µL per application (96-well plate) with at least 0.3 X 10
6 RLU / well.
3. Avoid freezing and thawing cycle to ensure the titer of the pseudovirus.
4. This product is for Research Use only
5. Neutralization assay protocol is available
SARS-CoV-1 Pseudovirus uses HIV pseudotyped with SARS-CoV-1 spike protein and firefly luciferase reporter. This pseudovirus effectively infects human ACE2 overexpressing cells and can be used to screen for inhibitors of Spike-ACE2 interaction, determine neutralizing antibody titers, and is a valuable tool for COVID-19 vaccine development as well.
DMEM/10% FBS
43740568
Surface glycoprotein
S
Severe acute respiratory syndrome coronavirus 2
Liquid
QHD43416
1791269090
Recombinant Protein Sequence:
Omicron Variant Spike BA.5 Met 1 - Cys 1251 (T19I, L24S, 25-27del, 69-70del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K)
Infectious Disease,COVID-19
HEK293 cells
P0DTC1